- Home
- MDIA vs IRD Comparison
MDIA vs IRD Comparison
Compare MDIA & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- IRD
- Stock Information
- Founded
- MDIA 2019
- IRD 2018
- Country
- MDIA United States
- IRD United States
- Employees
- MDIA N/A
- IRD N/A
- Industry
- MDIA Broadcasting
- IRD
- Sector
- MDIA Consumer Discretionary
- IRD
- Exchange
- MDIA Nasdaq
- IRD NYSE
- Market Cap
- MDIA 51.8M
- IRD 62.0M
- IPO Year
- MDIA N/A
- IRD N/A
- Fundamental
- Price
- MDIA $1.10
- IRD $0.95
- Analyst Decision
- MDIA
- IRD Strong Buy
- Analyst Count
- MDIA 0
- IRD 3
- Target Price
- MDIA N/A
- IRD $6.33
- AVG Volume (30 Days)
- MDIA 94.9K
- IRD 2.4M
- Earning Date
- MDIA 05-20-2025
- IRD 08-15-2025
- Dividend Yield
- MDIA N/A
- IRD N/A
- EPS Growth
- MDIA N/A
- IRD N/A
- EPS
- MDIA N/A
- IRD N/A
- Revenue
- MDIA $116,895,000.00
- IRD $13,651,000.00
- Revenue This Year
- MDIA N/A
- IRD $51.41
- Revenue Next Year
- MDIA N/A
- IRD $68.84
- P/E Ratio
- MDIA N/A
- IRD N/A
- Revenue Growth
- MDIA 268.03
- IRD N/A
- 52 Week Low
- MDIA $0.79
- IRD $0.65
- 52 Week High
- MDIA $5.73
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- MDIA 53.71
- IRD N/A
- Support Level
- MDIA $1.15
- IRD N/A
- Resistance Level
- MDIA $1.31
- IRD N/A
- Average True Range (ATR)
- MDIA 0.15
- IRD 0.00
- MACD
- MDIA 0.00
- IRD 0.00
- Stochastic Oscillator
- MDIA 34.48
- IRD 0.00
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.